Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ES12 is a non-specific identifier used across various scientific domains. In the context of drug development, 'ES12' refers to a phenolic temozolomide (TMZ) ester analogue that has demonstrated promising in vitro activity against glioblastoma multiforme cell lines, including those resistant to TMZ. Research has focused on its stability and potential for further progression in drug development. Additionally, 'ES12' identifies a monoclonal antibody developed to recognize glycated apolipoprotein B epitopes, which is used to measure glycated LDL concentrations and holds diagnostic and pathophysiologic importance, particularly in diabetes. Another 'ES12' is a *Lactobacillus* strain isolated from Iranian native chickens, characterized for its probiotic potential, including antimicrobial activity and adhesion to Caco-2 cells, suggesting its possible use in the poultry industry.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ES12.